These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Two new fluoroquinolones. Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502 [No Abstract] [Full Text] [Related]
8. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria. Moros M; Coll R; Esteve M; Parés J; Xicota MA Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373 [No Abstract] [Full Text] [Related]
9. [Apropos of the status of new fluoroquinolones in treatment of acute sinusitis]. Beucler A; Garre M; Polonowski JM Presse Med; 1999 Nov; 28(37):2040-1. PubMed ID: 10605473 [No Abstract] [Full Text] [Related]
10. Effectiveness of fluoroquinolones against gram-positive bacteria. Bush K; Goldschmidt R Curr Opin Investig Drugs; 2000 Sep; 1(1):22-30. PubMed ID: 11249591 [TBL] [Abstract][Full Text] [Related]
11. [The use of Maxaquin (lomefloxacin hydrochloride) in the treatment of nonspecific inflammatory diseases and in the prevention of surgical interventions in urology]. Derevianko II; Lopatkin NA; Khodyreva LA; Kondrat'eva EM Urol Nefrol (Mosk); 1998; (5):14-8. PubMed ID: 9820038 [No Abstract] [Full Text] [Related]
12. Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects. Gootz TD; Brighty KE Med Res Rev; 1996 Sep; 16(5):433-86. PubMed ID: 8865150 [No Abstract] [Full Text] [Related]
13. Development of resistant bacteria isolated from dogs with otitis externa or urinary tract infections after exposure to enrofloxacin in vitro. Brothers AM; Gibbs PS; Wooley RE Vet Ther; 2002; 3(4):493-500. PubMed ID: 12584687 [TBL] [Abstract][Full Text] [Related]
15. [Efflux pumps of gram-positive bacteria and resistance to fluoroquionolones]. Egorov AM; Sazykin IuO Antibiot Khimioter; 2001; 46(8):3-5. PubMed ID: 11871317 [No Abstract] [Full Text] [Related]
16. Overview of the fluoroquinolone antibiotics. Just PM Pharmacotherapy; 1993; 13(2 Pt 2):4S-17S. PubMed ID: 8386356 [TBL] [Abstract][Full Text] [Related]
17. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Almer LS; Hoffrage JB; Keller EL; Flamm RK; Shortridge VD Antimicrob Agents Chemother; 2004 Jul; 48(7):2771-7. PubMed ID: 15215148 [TBL] [Abstract][Full Text] [Related]
18. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates. Montanari MP; Mingoia M; Varaldo PE Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353 [TBL] [Abstract][Full Text] [Related]
19. [Effectiveness of a new fluoroquinolone antibiotic avelox in the treatment of suppurative sinusitis]. Egorov VI; Kozarenko AV Vestn Otorinolaringol; 2002; (5):35-6. PubMed ID: 12524963 [No Abstract] [Full Text] [Related]
20. [Efficacy of lomefloxacin and ofloxacin in complex therapy of infections in patients with burns]. Krutikov MG; Alekseev AA; Bobrovnikov AE; Grishina IA; Elagina LV; Izotova GN; Iakovlev VP Antibiot Khimioter; 1998; 43(10):27-31. PubMed ID: 9825107 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]